Pulse Biosciences, Inc. (NASDAQ: PLSE) has begun enrolling patients in a multi‑center, first‑in‑human feasibility study of its nPulse™ Vybrance™ Percutaneous Electrode System for the treatment of T1N0M0 papillary thyroid microcarcinoma, the most common form of thyroid cancer. The study, which began on March 12 2026, will evaluate the safety and efficacy of the company’s nanosecond pulsed‑field ablation (nsPFA) technology in patients with small, slow‑growing thyroid tumors. The trial is being conducted under an Investigational Device Exemption (IDE) and will assess lesion durability, symptom improvement, and the potential to reduce the need for surgical intervention.
The enrollment milestone marks a significant expansion of Pulse Biosciences’ clinical portfolio beyond its existing atrial fibrillation and benign thyroid nodule programs. By moving nsPFA into a malignant indication, the company is positioning itself to capture a broader market for its non‑thermal ablation platform, which offers tissue‑sparing benefits over traditional thermal methods. The study involves collaboration with Sarasota Memorial Health Care System and The University of Texas MD Anderson Cancer Center, two leading institutions that enhance the trial’s credibility and potential for robust data collection.
Management emphasized the strategic importance of the new trial. CEO and Co‑Chairman Paul LaViolette stated, “We believe the non‑thermal mechanism of action of nsPFA positions our nPulse technology as a potential treatment option for both benign and malignant thyroid tumors. Commencing these first‑in‑human feasibility cases in collaboration with world‑class institutions is an important initial step and is consistent with our mission to rigorously generate data and demonstrate the potential to improve patient outcomes and provide clinicians with more precise, tissue‑sparing tools for minimally invasive treatment applications.”
The trial’s initiation also signals progress toward a future regulatory submission for the device in the thyroid cancer indication. A successful safety and efficacy profile could accelerate the company’s path to market approval, potentially opening a sizable addressable market for a minimally invasive alternative to surgery or surveillance in low‑risk thyroid cancer patients. The expansion into a malignant indication complements the company’s existing atrial fibrillation and benign nodule programs, creating a diversified pipeline that can mitigate risk and enhance long‑term growth prospects.
Market reaction to the announcement was positive, driven by investor enthusiasm for the nsPFA platform’s potential to disrupt multiple soft‑tissue ablation markets. Analysts noted that the trial’s initiation aligns with Pulse Biosciences’ broader strategy to expand its nsPFA technology across therapeutic areas, reinforcing confidence in the company’s ability to generate future revenue streams despite its current pre‑revenue status.
revised_sentiment_rating":6}]} <|constrain|>}}
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.